AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Understanding what not to do when saving for retirement in your 30s can prevent costly mistakes. Educate yourself for a successful financial journey.
26,593 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
A dividend ETF with a 19-year monthly payout streak stands out in 2026 for steady income. Here’s how this 5-star pays...
SpaceX and Amazon share a blueprint for infrastructure growth, but their earnings paths diverge, forcing investors to...
Two century-old dividend histories anchor a growing conversation about reliable income in today’s volatile markets. Y...
Two pharma giants flashed a golden cross this month, but the stories behind AbbVie and Baxter diverge sharply for inc...
Oil jumps to $100 per barrel, sparking renewed interest in energy income strategies. This report breaks down XOMO, ML...
A new study shows a troubling planning gap among executives with equity awards. Despite financial savvy, 44% lack a f...
With megacap dominance fading, traders are rethinking how to beat without magnificent risk. Equal-weight strategies a...
Investors eyeing DEI in 2026 should study the Q1 results, leverage, and lease metrics that shape the office REIT's tr...
A leading AI scientist cautions that hyperintelligent machines with their own preservation goals could imperil humani...
Genius Sports reported a significant top-line gain, with revenue up sharply last quarter. But a prominent investor ch...
A $4.2 million estate can trigger a sizable tax gap based on the order of a couple’s deaths. This piece breaks down t...